International Journal of Particle Therapy最新文献

{"title":"Prostate Cancer Treatment with Pencil Beam Proton Therapy Using Rectal Spacers sans Endorectal Balloons.","authors":"Matthew Forsthoefel,&nbsp;Ryan Hankins,&nbsp;Elizabeth Ballew,&nbsp;Cara Frame,&nbsp;David DeBlois,&nbsp;Dalong Pang,&nbsp;Pranay Krishnan,&nbsp;Keith Unger,&nbsp;Keith Kowalczyk,&nbsp;John Lynch,&nbsp;Anatoly Dritschilo,&nbsp;Sean P Collins,&nbsp;Jonathan W Lischalk","doi":"10.14338/IJPT-21-00039","DOIUrl":"https://doi.org/10.14338/IJPT-21-00039","url":null,"abstract":"<p><strong>Purpose: </strong>Proton beam radiotherapy (PBT) has been used for the definitive treatment of localized prostate cancer with low rates of high-grade toxicity and excellent patient-reported quality-of-life metrics. Technological advances such as pencil beam scanning (PBS), Monte Carlo dose calculations, and polyethylene glycol gel rectal spacers have optimized prostate proton therapy. Here, we report the early clinical outcomes of patients treated for localized prostate cancer using modern PBS-PBT with hydrogel rectal spacing and fiducial tracking without the use of endorectal balloons.</p><p><strong>Materials and methods: </strong>This is a single institutional review of consecutive patients treated with histologically confirmed localized prostate cancer. Prior to treatment, all patients underwent placement of fiducials into the prostate and insertion of a hydrogel rectal spacer. Patients were typically given a prescription dose of 7920 cGy at 180 cGy per fraction using a Monte Carlo dose calculation algorithm. Acute and late toxicity were evaluated using the Common Terminology Criteria for Adverse Events (CTCAE), version 5. Biochemical failure was defined using the Phoenix definition.</p><p><strong>Results: </strong>From July 2018 to April 2020, 33 patients were treated (median age, 75 years). No severe acute toxicities were observed. The most common acute toxicity was urinary frequency. With a median follow-up of 18 months, there were no high-grade genitourinary late toxicities; however, one grade 3 gastrointestinal toxicity was observed. Late erectile dysfunction was common. One treatment failure was observed at 21 months in a patient treated for high-risk prostate cancer.</p><p><strong>Conclusion: </strong>Early clinical outcomes of patients treated with PBS-PBT using Monte Carlo-based planning, fiducial placement, and rectal spacers sans endorectal balloons demonstrate minimal treatment-related toxicity with good oncologic outcomes. Rectal spacer stabilization without the use of endorectal balloons is feasible for the use of PBS-PBT.</p>","PeriodicalId":36923,"journal":{"name":"International Journal of Particle Therapy","volume":"9 1","pages":"28-41"},"PeriodicalIF":1.7,"publicationDate":"2022-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238133/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40462132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proceedings to the 7th Annual Conference of the Particle Therapy Cooperative Group North America (PTCOG-NA)","authors":"A. Garda, Lindsay Morris, R. Finley, Sheri S Spreiter, N. Deiter, John V. Kruse, S. Ito, M. Haddock, Ivy, Petersen, Chin-Cheng Chen, F. Yu, Ping-Chung Tsai, J. Moreau, Chavanon Apinorasethkul, D. Boos, A. Shim, Haibo Lin, J. I. Choi","doi":"10.14338/IJPT-22-PTCOG-NA-8.4","DOIUrl":"https://doi.org/10.14338/IJPT-22-PTCOG-NA-8.4","url":null,"abstract":"Purpose : Cancer cells produce innate immune signals following detection of radiation-induced cytosolic DNA via signaling pathways such as cGAS-STING. High linear energy transfer (LET) radiations induce more DNA double-strand breaks (DSBs) per unit dose than low-LET radiations, potentially enhancing immunogenic effects. This work explores the in vitro dose response characteristics of pro-immunogenic interferon-beta (IFN b ) and cGAS-STING antagonist three-prime repair exonuclease 1 (TREX1) from varying-LET radiations. Methods : IFN b and TREX1 expression were measured in MCC13 cells irradiated with graded doses of x-rays or fast neutrons (comparable LET to carbon-12) via ELISA, immunofluorescence, and qPCR assays. Laboratory measurement of the RBE for IFN b production (RBE IFN b ) and TREX1 upregulation (RBE TREX1 ) was compared to the modeled RBE for DSB induction (RBE DSB ) from Monte Carlo DNA damage simulations. RBE IFN b models were applied to radiation transport simulations to quantify the potential secretion of IFN b from representative proton, helium-4, and carbon-12 beams. Results : Maximum IFN b secretions occurred at 5.7 Gy and 14.0 Gy for neutrons and x-rays, respectively (RBE IFN b of 2.5). TREX1 signal increased linearly, with a four-fold higher upregulation per unit dose for fast neutrons (RBE TREX1 of 4.0). Monte Carlo modeling suggests an enhanced Bragg peak-to-entrance ratio for IFNb production in charged particle beams. Conclusion : High-LET radiation initiates larger IFNb and TREX1 responses per unit dose than low-LET radiations. RBE IFN b is comparable to published values for RBE DSB , whereas RBE TREX1 is roughly twofold higher. Therapeutic advantages of high-LET versus low-LET radiation remain unclear. Potential TREX1-targeted interventions may enable IFNb-mediated immunogenic responses at lower doses of high-LET radiations. Aim : To implement lattice radiotherapy using proton pencil beam scanning, and demonstrate treatments that are spatially fractionated in physical dose (PD), with significant escalation of biologic dose (BD) and dose-averaged linear energy transfer (LET d ) in the vicinity of the high PD regions. Method : For 5 patients with bulky tumors, spatial proton dose fractionation inside the GTV was achieved using proton lattice radiotherapy (pLRT). This involves a 3D lattice of 1.5-cm diameter spherical dose regions separated by 3 cm on average. pLRT plans were created with Eclipse (Varian Medical Systems). Two fields with an opening angle of at least 40 degrees were used to reduce skin dose at entrance. Dose valleys between spheres were kept below 40% of the peak PD. The resulting LET d distributions were calculated with an in-house GPU-based Monte Carlo simulation. BD was estimated from LET d and PD by using published formulae that are based on the linear-quadratic model, as well as a simpler model that assumes a linear relationship between BD and the product of LET d (in keV/ l m) and PD: BD ¼ 1.1PD(0.08LET d","PeriodicalId":36923,"journal":{"name":"International Journal of Particle Therapy","volume":"8 1","pages":"82 - 122"},"PeriodicalIF":1.7,"publicationDate":"2022-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48743679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dosimetric Comparison of Various Spot Placement Techniques in Proton Pencil Beam Scanning.","authors":"Mahboob Ur Rehman,&nbsp;Omar A Zeidan,&nbsp;Twyla Willoughby,&nbsp;Sanford L Meeks,&nbsp;Patrick Kelly,&nbsp;Kevin Erhart","doi":"10.14338/IJPT-21-00022.1","DOIUrl":"https://doi.org/10.14338/IJPT-21-00022.1","url":null,"abstract":"<p><strong>Purpose: </strong>To present quantitative dosimetric evaluations of five proton pencil beam spot placement techniques.</p><p><strong>Materials and methods: </strong>The spot placement techniques that were investigated include two grid-based (rectilinear grid and hexagonal grid, both commonly available in commercial planning systems) and three boundary-contoured (concentric contours, hybrid, and optimized) techniques. Treatment plans were created for two different target volumes, one spherical and one conical. An optimal set of planning parameters was defined for all treatment plans and the impact of spot placement techniques on the plan quality was evaluated in terms of lateral/distal dose falloff, normal tissue sparing, conformity and homogeneity of dose distributions, as well as total number of spots used.</p><p><strong>Results: </strong>The results of this work highlight that for grid-based spot placement techniques, the dose conformity is dependent on target cross-sectional shape perpendicular to beam direction, which changes for each energy layer. This variable conformity problem is mitigated by using boundary contoured spot placement techniques. However, in the case of concentric contours, the conformity is improved but at the cost of decreased homogeneity inside the target. Hybrid and optimized spot placement techniques, which use contoured spots at the boundary and gridlike interior spot patterns, provide more uniform dose distributions inside the target volume while maintaining the improved dose conformity. The optimized spot placement technique improved target coverage, homogeneity of dose, and minimal number of spots. The dependence of these results on spot size is also presented for both target shapes.</p><p><strong>Conclusion: </strong>This work illustrates that boundary-contoured spot placement techniques offer marked improvement in dosimetry metrics when compared to commercially available grid-based techniques for a range of proton scanned beam spot sizes.</p>","PeriodicalId":36923,"journal":{"name":"International Journal of Particle Therapy","volume":"9 1","pages":"54-63"},"PeriodicalIF":1.7,"publicationDate":"2022-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238129/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40462133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hyperfractionated-Accelerated Reirradiation with Proton Therapy for Radiation-Associated Breast Angiosarcoma","authors":"W. S. Looi, J. Bradley, Xiaoying Liang, Christiana M. Shaw, Mark M. Leyngold, R. M. Mailhot Vega, E. Brooks, M. Rutenberg, L. Spiguel, F. Giap, N. Mendenhall","doi":"10.14338/ijpt-21-00031.1","DOIUrl":"https://doi.org/10.14338/ijpt-21-00031.1","url":null,"abstract":"Purpose Radiation-associated angiosarcoma (RAAS) is a rare complication among patients treated with radiation therapy for breast cancer. Hyperfractionated-accelerated reirradiation (HART) improves local control after surgery. Proton therapy may further improve the therapeutic ratio by mitigating potential toxicity. Materials and Methods Six patients enrolled in a prospective registry with localized RAAS received HART with proton therapy between 2015 and 2021. HART was delivered twice or thrice daily in fraction sizes of 1.5 or 1.0 Gy, respectively. All patients received 45 Gy to a large elective volume followed by boosts to a median dose of 65 (range, 60-75) Gy. Toxicity was recorded prospectively by using the Common Terminology Criteria for Adverse Events, version 4.0. Results The median follow-up duration was 1.5 (range, 0.25-2.9) years. The median age at RAAS diagnosis was 73 (range, 60-83) years with a median latency of 8.9 (range, 5-14) years between radiation therapy completion and RAAS diagnosis. The median mean heart dose was 2.2 (range, 0.1-4.96) Gy. HART was delivered postoperatively (n = 1), preoperatively (n = 3), preoperatively for local recurrence after initial management with mastectomy (n = 1), and as definitive treatment (n = 1). All patients had local control of disease throughout follow-up. Three of 4 patients treated preoperatively had a pathologic complete response. The patient treated definitively had a complete metabolic response on her posttreatment PET/CT (positron emission tomography–computed tomography) scan. Two patients developed distant metastatic disease despite local control and died of their disease. Acute grade 3 toxicity occurred in 3 patients: 2 patients undergoing preoperative HART experienced wound dehiscence and 1 postoperatively developed grade 3 wound infection, which resolved. Conclusion HART with proton therapy appears effective for local control of RAAS with a high rate of pathologic complete response and no local recurrences to date. However, vigilant surveillance for distant metastasis should occur. Toxicity is comparable to that in photon/electron series. Proton therapy for RAAS may maximize normal tissue sparing in this large-volume reirradiation setting.","PeriodicalId":36923,"journal":{"name":"International Journal of Particle Therapy","volume":"8 1","pages":"55 - 67"},"PeriodicalIF":1.7,"publicationDate":"2022-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46235465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dosimetric Results for Adjuvant Proton Radiation Therapy of HPV-Associated Oropharynx Cancer","authors":"C. Wright, J. Baron, Daniel Y. Lee, Michele M. Kim, A. Barsky, B. Teo, J. Lukens, S. Swisher-McClure, A. Lin","doi":"10.14338/IJPT-D-21-00018","DOIUrl":"https://doi.org/10.14338/IJPT-D-21-00018","url":null,"abstract":"Purpose One significant advantage of proton therapy is its ability to improve normal tissue sparing and toxicity mitigation, which is relevant in the treatment of oropharyngeal squamous cell carcinoma (OPSCC). Here, we report our institutional experience and dosimetric results with adjuvant proton radiation therapy (PRT) versus intensity-modulated radiotherapy (IMRT) for Human Papilloma Virus (HPV)-associated OPSCC. Materials and Methods This was a retrospective, single institutional study of all patients treated with adjuvant PRT for HPV-associated OPSCC from 2015 to 2019. Each patient had a treatment-approved equivalent IMRT plan to serve as a reference. Endpoints included dosimetric outcomes to the organs at risk (OARs), local regional control (LRC), progression-free survival (PFS), and overall survival (OS). Descriptive statistics, a 2-tailed paired t test for dosimetric comparisons, and the Kaplan-Meier method for disease outcomes were used. Results Fifty-three patients were identified. Doses delivered to OARs compared favorably for PRT versus IMRT, particularly for the pharyngeal constrictors, esophagus, larynx, oral cavity, and submandibular and parotid glands. The achieved normal tissue sparing did not negatively impact disease outcomes, with 2-year LRC, PFS, and OS of 97.0%, 90.3%, and 97.5%, respectively. Conclusion Our study suggests that meaningful normal tissue sparing in the postoperative setting is achievable with PRT, without impacting disease outcomes.","PeriodicalId":36923,"journal":{"name":"International Journal of Particle Therapy","volume":"8 1","pages":"47 - 54"},"PeriodicalIF":1.7,"publicationDate":"2021-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46578073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proton Radiotherapy for Patients With Oligometastatic Breast Cancer Involving the Sternum.","authors":"Andrew Johnson,&nbsp;Nicolas Depauw,&nbsp;Stephen Zieminski,&nbsp;Rachel Jimenez","doi":"10.14338/IJPT-21-00014","DOIUrl":"https://doi.org/10.14338/IJPT-21-00014","url":null,"abstract":"<p><strong>Introduction: </strong>A subset of metastatic breast cancer patients present with oligometastatic disease involving the sternum. Given the proximity to traditional target structures, a proton radiation field can be expanded to include this region, providing definitive therapy for patients who are otherwise metastatic. We evaluated the feasibility and outcomes of a small series of patients who received comprehensive nodal irradiation inclusive of an isolated sternal metastasis using proton pencil beam scanning.</p><p><strong>Materials and methods: </strong>Four patients with a diagnosis of metastatic breast cancer with an isolated metastasis to the sternum received multimodality therapy with curative intent and then underwent adjuvant pencil beam scanning with definitive treatment to the sternum. Dosimetric parameters and treatment outcomes were evaluated.</p><p><strong>Results: </strong>With respect to treatment coverage, proton therapy was able to deliver comprehensive target structure coverage while maintaining modest doses to the organs at risk compared with photon techniques. At a median follow-up of 28 months from diagnosis, none of the patients have experienced relapse within the radiation portal or developed additional sites of metastatic disease.</p><p><strong>Conclusion: </strong>Pencil beam scanning for oligometastatic breast cancer with isolated sternal lesions appears feasible without undue normal tissue exposure. Current treatment outcomes appear promising.</p>","PeriodicalId":36923,"journal":{"name":"International Journal of Particle Therapy","volume":"8 3","pages":"66-71"},"PeriodicalIF":1.7,"publicationDate":"2021-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8768896/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39592766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiation-Induced Toxicity Risks in Photon Versus Proton Therapy for Synchronous Bilateral Breast Cancer","authors":"L. Stick, M. F. Jensen, S. Bentzen, C. Kamby, A. Y. Lundgaard, M. Maraldo, B. Offersen, Jen Yu, I. Vogelius","doi":"10.14338/IJPT-21-00023.1","DOIUrl":"https://doi.org/10.14338/IJPT-21-00023.1","url":null,"abstract":"Purpose This study compares photon and proton therapy plans for patients with synchronous bilateral early breast cancer and estimates risks of early and late radiation-induced toxicities. Materials and Methods Twenty-four patients with synchronous bilateral early breast cancer receiving adjuvant radiation therapy using photons, 3-dimensional conformal radiation therapy or volumetric modulated arc therapy, were included and competing pencil beam scanning proton therapy plans were created. Risks of dermatitis, pneumonitis, acute esophageal toxicity, lung and breast fibrosis, hypothyroidism, secondary lung and esophageal cancer and coronary artery events were estimated using published dose-response relationships and normal tissue complication probability (NTCP) models. Results The primary clinical target volume V95% and/or nodal clinical target volume V90% were less than 95% in 17 photon therapy plans and none of the proton plans. Median NTCP of radiation dermatitis ≥ grade 2 was 18.3% (range, 5.4-41.7) with photon therapy and 58.4% (range, 31.4-69.7) with proton therapy. Median excess absolute risk (EAR) of secondary lung cancer at age 80 for current and former smokers was 4.8% (range, 0.0-17.0) using photons and 2.7% (range, 0.0-13.6) using protons. Median EAR of coronary event at age 80, assuming all patients have preexisting cardiac risk factors, was 1.0% (range, 0.0-5.6) with photons and 0.2% (range, 0.0-1.3) with protons. Conclusion Proton therapy plans improved target coverage and reduced risk of coronary artery event and secondary lung cancer while increasing the risk of radiation dermatitis.","PeriodicalId":36923,"journal":{"name":"International Journal of Particle Therapy","volume":"8 1","pages":"1 - 13"},"PeriodicalIF":1.7,"publicationDate":"2021-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45578046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating Disparities in Proton Radiation Therapy Use in AHOD1331, a Contemporary Children's Oncology Group Trial for Advanced-Stage Hodgkin Lymphoma.","authors":"Raymond B Mailhot Vega,&nbsp;Sharon M Castellino,&nbsp;Qinglin Pei,&nbsp;Susan Parsons,&nbsp;Kenneth B Roberts,&nbsp;David Hodgson,&nbsp;Anne-Marie Charpentier,&nbsp;Thomas J Fitzgerald,&nbsp;Sandy K Kessel,&nbsp;Frank G Keller,&nbsp;Kara Kelly,&nbsp;Bradford S Hoppe","doi":"10.14338/IJPT-21-00012.1","DOIUrl":"https://doi.org/10.14338/IJPT-21-00012.1","url":null,"abstract":"","PeriodicalId":36923,"journal":{"name":"International Journal of Particle Therapy","volume":"8 3","pages":"55-57"},"PeriodicalIF":1.7,"publicationDate":"2021-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8768892/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39592765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term Clinical Outcomes in Favorable Risk Prostate Cancer Patients Receiving Proton Beam Therapy","authors":"A. Bao, A. Barsky, R. Maxwell, J. Bekelman, S. Both, J. Christodouleas, C. Deville, P. Fang, Z. Tochner, N. Vapiwala","doi":"10.14338/IJPT-21-00016","DOIUrl":"https://doi.org/10.14338/IJPT-21-00016","url":null,"abstract":"Purpose Long-term data regarding the disease control outcomes of proton beam therapy (PBT) for patients with favorable risk intact prostate cancer (PC) are limited. Herein, we report our institution's long-term disease control outcomes in PC patients with clinically localized disease who received PBT as primary treatment. Methods One hundred sixty-six favorable risk PC patients who received definitive PBT to the prostate gland at our institution from 2010 to 2012 were retrospectively assessed. The outcomes studied were biochemical failure-free survival (BFFS), biochemical failure, local failure, regional failure, distant failure, PC-specific survival, and overall survival. Patterns of failure were also analyzed. Multivariate Cox proportional hazards modeling was used to estimate independent predictors of BFFS. Results The median length of follow-up was 8.3 years (range, 1.2–10.5 years). The majority of patients had low-risk disease (58%, n = 96), with a median age of 64 years at the onset of treatment. Of 166 treated men, 13 (7.8%), 8 (4.8%), 2 (1.2%) patient(s) experienced biochemical failure, local failure, regional failure, respectively. Regional failure was seen in an obturator lymph node in 1 patient and the external iliac lymph nodes in the other. None of the patients experienced distant failure. There were 5 (3.0%) deaths, none of which were due to PC. The 5- and 8-year BFFS rate were 97% and 92%, respectively. None of the clinical disease characteristics or treatment-related factors assessed were associated with BFFS on multivariate Cox proportional hazards modeling (all P > .05). Conclusion Disease control rates reported in our assessment of PBT were similar to those reported in previous clinically localized intact PC analyses, which used intensity-modulated radiotherapy, three-dimensional conformal radiotherapy, or radical prostatectomy as definitive therapy. In addition, BFFS rates were similar, if not improved, to previous PBT studies.","PeriodicalId":36923,"journal":{"name":"International Journal of Particle Therapy","volume":"8 1","pages":"14 - 24"},"PeriodicalIF":1.7,"publicationDate":"2021-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46632362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pericardial Effusion during Proton Therapy in a Patient with Chemorefractory Hodgkin Lymphoma.","authors":"Ashley Way, Savas Ozdemir, Barbara Berges, Nataliya Getman, Xiaoying Liang, Nancy P Mendenhall, Graham Collins, David Cutter, Raymond B Mailhot Vega","doi":"10.14338/IJPT-21-00010","DOIUrl":"10.14338/IJPT-21-00010","url":null,"abstract":"<p><p>We present a case of recurrent pericardial effusion presenting during proton therapy in a 24-year-old female receiving mediastinal treatment for classical Hodgkin lymphoma. Pericardial effusion is typically considered an event accompanying lymphoma diagnosis or as a subacute or late effect of radiotherapy. Rarely has it been described as occurring during radiation treatment with photon-based radiotherapy, let alone proton therapy. It is unclear what underlying cause triggered recurrent effusion in this patient. Identifying and managing pericardial effusion during treatment delivery is important to consider as it may affect radiation dosimetry, particularly with proton therapy. Doing so will help ensure patients receive optimal treatment and minimize the risks of morbidity and mortality.</p>","PeriodicalId":36923,"journal":{"name":"International Journal of Particle Therapy","volume":"8 1","pages":"76-81"},"PeriodicalIF":2.1,"publicationDate":"2021-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9009456/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49537914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}